The correct choice of excipient in the formulation of a new or redeveloped drug product is critical for the success of any formulation program. Novozymes' recombinant human serum albumins (rAlbumins) offer drug manufacturers a powerful formulation solution by providing a quality product based on comprehensive understanding of both its physical and functional properties. These characteristics allow faster development of safe and stable formulations of even challenging drug candidates.
This whitepaper from Novozymes will explore the usage of a multifunctional excipient, rAlbumin, that acts to stabilize the drug product by reducing aggregation, oxidation, and surface adsorption. Particularly valuable for liquid formulations, rAlbumin can significantly decrease the attrition rate in formulation development and provides increased freedom to choose the best candidate for further development.
If you are keen to find out more, click here to download this whitepaper now!
Novozymes develops and manufactures high quality animal-free, Q7 GMP compliant ingredients and technologies to support product development in medical device and pharmaceutical industry. With over 25 years experience in the pharmaceutical industry, Novozymes Biopharma is the world leader in the supply of biological based ingredients such as hyaluronic acid and recombinant albumin, and technologies for formulations and processing.
By combining Novozymes' unique knowledge around our biological solutions with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products. For further information visit www.biopharma.novozymes.com